Analysts Recommend Rocket Pharmaceuticals as a Top Buy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy RCKT?
Source: Yahoo Finance
- Price Target Adjustment: Morgan Stanley lowered Rocket Pharmaceuticals' price target from $7 to $5 while maintaining an Equal Weight rating, reflecting ongoing optimism for small-to-mid cap biotech amid large-cap biopharma's patent cliff.
- Clinical Milestones: In Q3 2025, Rocket Pharmaceuticals achieved significant progress as the FDA lifted the clinical hold on RP-A501, with plans to resume trials in H1 2026, marking a major breakthrough in Danon disease treatment.
- Commercialization Progress: The FDA set a PDUFA action date of March 28 for KRESLADI, a gene therapy, which represents a critical step toward the company's first potential commercial launch, expected to drive revenue growth.
- Strategic Focus: While advancing cardiovascular products RP-A601 and RP-A701, Rocket Pharmaceuticals remains focused on hematology programs and anticipates receiving a Rare Pediatric Disease Priority Review Voucher upon KRESLADI's approval, enhancing its market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCKT
Wall Street analysts forecast RCKT stock price to rise
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 5.110
Low
5.00
Averages
8.63
High
16.00
Current: 5.110
Low
5.00
Averages
8.63
High
16.00
About RCKT
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rocket Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: Rocket Pharmaceuticals reported a Q4 GAAP EPS of -$0.38, beating expectations by $0.07, indicating an improvement in financial performance that could bolster investor confidence.
- Cash Position: As of December 31, 2025, Rocket Pharmaceuticals had $188.9 million in cash, cash equivalents, and investments, providing ample funding for future R&D and operations, ensuring its sustained growth in the competitive biopharmaceutical market.
- Market Outlook: The deep dislocation surrounding LAD-I approval and the amended Danon program offers investors asymmetric upside potential, suggesting that the company's strategic positioning in drug development could yield significant market returns.
- Industry Conference Participation: Rocket Pharmaceuticals' presentations at the 44th Annual J.P. Morgan Healthcare Conference and Evercore's 8th Annual Healthcare Conference further enhance its visibility and influence within the industry, helping to attract potential investors and partners.
See More
Overview of FDA Regulatory Developments
- BHA Safety Reassessment: On February 10, 2026, the FDA initiated a comprehensive reassessment of Butylated Hydroxyanisole (BHA) to evaluate its safety in food and food contact substances based on the latest scientific data, despite its classification as a potential human carcinogen in animal studies, which could affect consumer confidence in food safety.
- Hormone Therapy Labeling Updates: On February 12, 2026, the FDA approved labeling updates for six menopausal hormone therapy products, including Prometrium and Divigel, clarifying risk considerations and removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia, which may enhance market acceptance of these therapies.
- Innovative Device Approval: On the same day, the FDA approved Novocure's Optune Pax, a first-of-its-kind device for treating locally advanced pancreatic cancer, marking a significant technological advancement in cancer treatment and potentially providing new options for patients.
- Biotech Stocks Under Scrutiny: With upcoming FDA decisions in March 2026, biotech stocks are under market scrutiny, and investors should closely monitor the potential impacts of these decisions on related companies, which could trigger market volatility.
See More
Analysts Recommend Rocket Pharmaceuticals as a Top Buy
- Price Target Adjustment: Morgan Stanley lowered Rocket Pharmaceuticals' price target from $7 to $5 while maintaining an Equal Weight rating, reflecting ongoing optimism for small-to-mid cap biotech amid large-cap biopharma's patent cliff.
- Clinical Milestones: In Q3 2025, Rocket Pharmaceuticals achieved significant progress as the FDA lifted the clinical hold on RP-A501, with plans to resume trials in H1 2026, marking a major breakthrough in Danon disease treatment.
- Commercialization Progress: The FDA set a PDUFA action date of March 28 for KRESLADI, a gene therapy, which represents a critical step toward the company's first potential commercial launch, expected to drive revenue growth.
- Strategic Focus: While advancing cardiovascular products RP-A601 and RP-A701, Rocket Pharmaceuticals remains focused on hematology programs and anticipates receiving a Rare Pediatric Disease Priority Review Voucher upon KRESLADI's approval, enhancing its market competitiveness.
See More
KBRA Assigns Ratings to $548.3 Million RCKT Mortgage Trust 2026-CES1
- Transaction Size: The RCKT 2026-CES1 mortgage trust has a transaction size of $548.3 million, consisting entirely of newly originated closed-end second lien mortgages issued by Rocket Mortgage, indicating sustained market demand for new loan products.
- Loan Characteristics: The trust's loan pool comprises 5,839 fully amortizing, fixed-rate mortgages with average terms of 10 years (4.1%), 15 years (7.8%), 20 years (62.7%), and 30 years (25.5%), reflecting a diverse range of loan term options.
- Rating Methodology: KBRA employs its Residential Asset Loss Model (REALM) for loan-level analysis of the mortgage pool, supplemented by third-party due diligence results and cash flow modeling analysis, ensuring the accuracy and reliability of the ratings, thereby enhancing market confidence.
- Legal Structure Review: During the rating process, KBRA also assessed the legal structure and documentation of the transaction, ensuring compliance of all key transaction parties, which reduces investment risk and increases investor trust.
See More
Avant Technologies Strengthens Clinical Validation for α-Klotho Therapy
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of α-Klotho in vascular health, providing scientific backing for its Klothonova therapy developed in partnership with Singapore's Austrianova, which is expected to enhance market acceptance of the therapy.
- Significant Market Potential: The precision medicine market is projected to grow from $119 billion in 2025 to $471 billion by 2034, and Avant's technological innovations align perfectly with this trend, positioning the company to capture a significant share of the future market.
- Deepened Strategic Collaboration: The exclusive global licensing agreement with Klothea Bio grants Klothonova rights to develop and commercialize Klotho-producing cells, leveraging Austrianova's technology, which is anticipated to accelerate the product's market entry.
- Diversified Investment Strategy: Avant is also collaborating with SGAustria to provide funding over the next eight months for diabetes treatment, demonstrating its strategic intent to expand across multiple therapeutic areas.
See More
Avant Technologies Strengthens Clinical Validation of α-Klotho, Advancing Cell Therapy Progress
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of the 'longevity protein' α-Klotho in vascular health, bolstering the scientific foundation for its joint venture Klothonova with Singapore's Austrianova, advancing cell therapy development.
- Significant Market Potential: As precision medicine expands, the sector is projected to grow from $119 billion in 2025 to $471 billion by 2034, positioning Avant Technologies at the forefront of this transformation, particularly in rare disease treatments.
- Innovative Technology: Klothonova's cell therapy aims to sustainably restore α-Klotho levels using genetically modified human cells, which is expected to revolutionize cardiovascular health and overall longevity, addressing the increasing market demand.
- Strategic Investment: Avant Technologies' joint venture Insulinova with SGAustria aims to develop an efficient diabetes treatment, with initial funding expected in the next eight months to drive innovative solutions for global diabetes patients.
See More
Rocket Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Highlights: Rocket Pharmaceuticals reported a Q4 GAAP EPS of -$0.38, beating expectations by $0.07, indicating an improvement in financial performance that could bolster investor confidence.
- Cash Position: As of December 31, 2025, Rocket Pharmaceuticals had $188.9 million in cash, cash equivalents, and investments, providing ample funding for future R&D and operations, ensuring its sustained growth in the competitive biopharmaceutical market.
- Market Outlook: The deep dislocation surrounding LAD-I approval and the amended Danon program offers investors asymmetric upside potential, suggesting that the company's strategic positioning in drug development could yield significant market returns.
- Industry Conference Participation: Rocket Pharmaceuticals' presentations at the 44th Annual J.P. Morgan Healthcare Conference and Evercore's 8th Annual Healthcare Conference further enhance its visibility and influence within the industry, helping to attract potential investors and partners.
See More
Overview of FDA Regulatory Developments
- BHA Safety Reassessment: On February 10, 2026, the FDA initiated a comprehensive reassessment of Butylated Hydroxyanisole (BHA) to evaluate its safety in food and food contact substances based on the latest scientific data, despite its classification as a potential human carcinogen in animal studies, which could affect consumer confidence in food safety.
- Hormone Therapy Labeling Updates: On February 12, 2026, the FDA approved labeling updates for six menopausal hormone therapy products, including Prometrium and Divigel, clarifying risk considerations and removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia, which may enhance market acceptance of these therapies.
- Innovative Device Approval: On the same day, the FDA approved Novocure's Optune Pax, a first-of-its-kind device for treating locally advanced pancreatic cancer, marking a significant technological advancement in cancer treatment and potentially providing new options for patients.
- Biotech Stocks Under Scrutiny: With upcoming FDA decisions in March 2026, biotech stocks are under market scrutiny, and investors should closely monitor the potential impacts of these decisions on related companies, which could trigger market volatility.
See More
Analysts Recommend Rocket Pharmaceuticals as a Top Buy
- Price Target Adjustment: Morgan Stanley lowered Rocket Pharmaceuticals' price target from $7 to $5 while maintaining an Equal Weight rating, reflecting ongoing optimism for small-to-mid cap biotech amid large-cap biopharma's patent cliff.
- Clinical Milestones: In Q3 2025, Rocket Pharmaceuticals achieved significant progress as the FDA lifted the clinical hold on RP-A501, with plans to resume trials in H1 2026, marking a major breakthrough in Danon disease treatment.
- Commercialization Progress: The FDA set a PDUFA action date of March 28 for KRESLADI, a gene therapy, which represents a critical step toward the company's first potential commercial launch, expected to drive revenue growth.
- Strategic Focus: While advancing cardiovascular products RP-A601 and RP-A701, Rocket Pharmaceuticals remains focused on hematology programs and anticipates receiving a Rare Pediatric Disease Priority Review Voucher upon KRESLADI's approval, enhancing its market competitiveness.
See More
KBRA Assigns Ratings to $548.3 Million RCKT Mortgage Trust 2026-CES1
- Transaction Size: The RCKT 2026-CES1 mortgage trust has a transaction size of $548.3 million, consisting entirely of newly originated closed-end second lien mortgages issued by Rocket Mortgage, indicating sustained market demand for new loan products.
- Loan Characteristics: The trust's loan pool comprises 5,839 fully amortizing, fixed-rate mortgages with average terms of 10 years (4.1%), 15 years (7.8%), 20 years (62.7%), and 30 years (25.5%), reflecting a diverse range of loan term options.
- Rating Methodology: KBRA employs its Residential Asset Loss Model (REALM) for loan-level analysis of the mortgage pool, supplemented by third-party due diligence results and cash flow modeling analysis, ensuring the accuracy and reliability of the ratings, thereby enhancing market confidence.
- Legal Structure Review: During the rating process, KBRA also assessed the legal structure and documentation of the transaction, ensuring compliance of all key transaction parties, which reduces investment risk and increases investor trust.
See More
Avant Technologies Strengthens Clinical Validation for α-Klotho Therapy
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of α-Klotho in vascular health, providing scientific backing for its Klothonova therapy developed in partnership with Singapore's Austrianova, which is expected to enhance market acceptance of the therapy.
- Significant Market Potential: The precision medicine market is projected to grow from $119 billion in 2025 to $471 billion by 2034, and Avant's technological innovations align perfectly with this trend, positioning the company to capture a significant share of the future market.
- Deepened Strategic Collaboration: The exclusive global licensing agreement with Klothea Bio grants Klothonova rights to develop and commercialize Klotho-producing cells, leveraging Austrianova's technology, which is anticipated to accelerate the product's market entry.
- Diversified Investment Strategy: Avant is also collaborating with SGAustria to provide funding over the next eight months for diabetes treatment, demonstrating its strategic intent to expand across multiple therapeutic areas.
See More
Avant Technologies Strengthens Clinical Validation of α-Klotho, Advancing Cell Therapy Progress
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of the 'longevity protein' α-Klotho in vascular health, bolstering the scientific foundation for its joint venture Klothonova with Singapore's Austrianova, advancing cell therapy development.
- Significant Market Potential: As precision medicine expands, the sector is projected to grow from $119 billion in 2025 to $471 billion by 2034, positioning Avant Technologies at the forefront of this transformation, particularly in rare disease treatments.
- Innovative Technology: Klothonova's cell therapy aims to sustainably restore α-Klotho levels using genetically modified human cells, which is expected to revolutionize cardiovascular health and overall longevity, addressing the increasing market demand.
- Strategic Investment: Avant Technologies' joint venture Insulinova with SGAustria aims to develop an efficient diabetes treatment, with initial funding expected in the next eight months to drive innovative solutions for global diabetes patients.
See More
